Your browser doesn't support javascript.
Neurologic manifestations associated with COVID-19: a multicentre registry.
Meppiel, Elodie; Peiffer-Smadja, Nathan; Maury, Alexandra; Bekri, Imen; Delorme, Cécile; Desestret, Virginie; Gorza, Lucas; Hautecloque-Raysz, Geoffroy; Landre, Sophie; Lannuzel, Annie; Moulin, Solène; Perrin, Peggy; Petitgas, Paul; SellaI, François; Wang, Adrien; Tattevin, Pierre; de Broucker, Thomas.
  • Meppiel E; Department of Neurology, Centre Hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France. Electronic address: elodie.meppiel@ch-stdenis.fr.
  • Peiffer-Smadja N; Department of Infectious Diseases, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France; Université de Paris, IAME, INSERM, Paris, France.
  • Maury A; Department of Neurology, Centre Hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France.
  • Bekri I; Department of Neurology and Stroke Center, Centre Hospitalier de Versailles, Le Chesnay, France.
  • Delorme C; Department of Neurology, Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • Desestret V; Department of Neuro-cognition and Neuro-ophthalmology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
  • Gorza L; Department of Neurology, Hôpital Foch, Suresnes, France.
  • Hautecloque-Raysz G; Department of Neurology, Hôpitaux civils de Colmar, Colmar, France.
  • Landre S; Department of Infectious Diseases, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
  • Lannuzel A; Department of Neurology, Centre Hospitalier Universitaire de la Guadeloupe, Faculté de médecine de l'université des Antilles, Centre d'investigation clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, France.
  • Moulin S; Department of Neurology, Centre Hospitalier Universitaire Reims, Hôpital Maison Blanche, Reims, France.
  • Perrin P; Department of Nephrology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Petitgas P; Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • SellaI F; Department of Neurology, Hôpitaux civils de Colmar, Colmar, France.
  • Wang A; Department of Neurology, Hôpital Foch, Suresnes, France.
  • Tattevin P; Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • de Broucker T; Department of Neurology, Centre Hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France.
Clin Microbiol Infect ; 27(3): 458-466, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-20242956
ABSTRACT

OBJECTIVES:

To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

METHODS:

We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020. All COVID-19 patients with de novo neurologic manifestations were eligible.

RESULTS:

We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France. Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61.3%) were male. COVID-19 was severe or critical in 102 patients (45.2%). The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30.2%), acute ischaemic cerebrovascular syndrome (57/222, 25.7%), encephalitis (21/222, 9.5%) and Guillain-Barré syndrome (15/222, 6.8%). Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barré syndrome. Brain imaging was performed in 192 patients (86.5%), including 157 magnetic resonance imaging (70.7%). Among patients with acute ischaemic cerebrovascular syndrome, 13 (22.8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28.1%) of 57. Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66.7%) of 21. Cerebrospinal fluid of 97 patients (43.7%) was analysed, with pleocytosis found in 18 patients (18.6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis. The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%).

CONCLUSIONS:

Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Registries / COVID-19 / Nervous System Diseases Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Registries / COVID-19 / Nervous System Diseases Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article